There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on McKesson (MCK – Research Report), Arcus Biosciences (RCUS – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.
McKesson (MCK)
Barclays analyst Stephanie Davis maintained a Buy rating on McKesson today and set a price target of $571.00. The company’s shares closed last Wednesday at $516.98, close to its 52-week high of $519.75.
According to TipRanks.com, Davis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for McKesson with a $545.90 average price target, representing a 7.0% upside. In a report issued on January 24, J.P. Morgan also maintained a Buy rating on the stock with a $564.00 price target.
See today’s best-performing stocks on TipRanks >>
Arcus Biosciences (RCUS)
In a report released yesterday, Peter Lawson from Barclays assigned a Buy rating to Arcus Biosciences, with a price target of $35.00. The company’s shares closed last Wednesday at $14.83, close to its 52-week low of $12.95.
According to TipRanks.com, Lawson is a 4-star analyst with an average return of
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $40.14, representing a 162.2% upside. In a report issued on January 30, Wedbush also initiated coverage with a Buy rating on the stock with a $30.00 price target.
Neurocrine (NBIX)
In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Neurocrine, with a price target of $154.00. The company’s shares closed last Wednesday at $136.29, close to its 52-week high of $143.35.
According to TipRanks.com, Ahmad is a 3-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Moderate Buy with an average price target of $143.89, which is a 6.6% upside from current levels. In a report issued on January 23, Barclays also maintained a Buy rating on the stock with a $150.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MCK:
